Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 499-512 , September 2007

Minimal residual disease assessment in chronic lymphocytic leukaemia

  • Hazem A. Sayala, MRCP(UK) (Clinical Reasearch Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 113 3926285; Fax: +44 113 3926286.
    • ,
  • Andy C. Rawstron, PhD (Principal Clinical Scientist)
    • ,
  • Peter Hillmen, MD, PhD (Consultant Haematologist)

References 

  1. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001 September 15;98(6):1746–1751
  2. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006 October;20(10):1783–1789
  3. Biondi A, Valsecchi MG, Seriu T, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia. 2000 November;14(11):1939–1943
  4. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet. 1998 November 28;352(9142):1731–1738
  5. Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard risk ALL patients detected by prospective MRD-monitoring during and after maintenance treatment - data from the GMALL 06/99 and 07/03 trials. Blood. 2007 Feb 1;109(3):910–915
  6. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Current Opinion in Hematology. 2005 January;12(1):33–39
  7. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005 October;90(10):1365–1372
  8. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. American Journal of Hematology. 1988;29(3):152–163
  9. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 June 15;87(12):4990–4997
  10. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001 July 1;98(1):29–35
  11. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997 October;11(10):1793–1798
  12. Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. The New England Journal of Medicine. 1983 December 29;309(26):1593–1599
  13. Owen RG, Johnson RJ, Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. Journal of Clinical Pathology. 1996 August;49(8):672–675
  14. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003 December;17(12):2257–2317
  15. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after marrow transplantation. Blood. 1996 September 15;88(6):2228–2235
  16. Bottcher S, Ritgen M, Pott C, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004 October;18(10):1637–1645
  17. Liang R, Chan V, Chan TK, et al. Detection of immunoglobulin gene rearrangement in lymphoid malignancies of B-cell lineage by seminested polymerase chain reaction gene amplification. American Journal of Hematology. 1993 May;43(1):24–28
  18. Aubin J, Davi F, Nguyen-Salomon F, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia. 1995 March;9(3):471–479
  19. Pfitzner T, Engert A, Wittor H, et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia. 2000 April;14(4):754–766
  20. van der Velden V, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003 June;17(6):1013–1034
  21. Bruggemann M, Droese J, Bolz I, et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 2000 August;14(8):1419–1425
  22. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006 June 1;107(11):4563–4569
  23. Vuillier F, Claisse JF, Vandenvelde C, et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leukemia & Lymphoma. 1992 June;7(3):195–204
  24. Lenormand B, Bizet M, Fruchart C, et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia. 1994 June;8(6):1019–1026
  25. Cabezudo E, Matutes E, Ramrattan M, et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia. 1997 November;11(11):1909–1914
  26. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992 July 1;80(1):29–36
  27. Hillmen P. Beyond detectable minimal residual disease in chronic lymphocytic leukemia. Seminars in Oncology. 2006 April;33(2 supplement 5):S23–S28
  28. Rawstron A, Villamor N, Zehnder J, et al. International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. ASH Annual Meeting Abstracts Abstract 15(104) 2004.
  29. Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukemia-specific assay for use in rituximab-containing regimens. Leukemia. 2006;20:2102–2110
  30. Rawstron AC, Villamore N, Ritgen M, et al. International Standardized Approach for Flow Cytometric Residual Disease Monitoring in Chronic Lymphocytic Leukemia. Leukemia 2007 May; 21(5):956–964.
  31. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 August 15;92(4):1165–1171
  32. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2001 March 1;19(5):1414–1420
  33. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. British Journal of Haematology. 2002 December;119(4):976–984
  34. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005 June 20;23(18):4079–4088
  35. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005 June 20;23(18):4070–4078
  36. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology. 2005 May 1;23(13):2971–2979
  37. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001 March;15(3):445–451
  38. Esteve J, Villamor N, Colomer D, et al. Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood. 2002 March 1;99(5):1873–1874
  39. Mattsson J, Uzunel M, Remberger M, et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia. 2000 February;14(2):247–254
  40. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005 January 1;105(1):397–404
  41. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 June;18(6):1093–1101
  42. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. The New England Journal of Medicine. 2000 December 14;343(24):1750–1757
  43. Bosch F, Ferrer A, Villamor N et al. Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL. ASH Annual Meeting Abstracts 106[Abstract 718] 2005.
  44. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001 September 1;98(5):1326–1331
  45. Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study. European Journal of Haematology. 2002 September;69(3):129–134
  46. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology. 2001 April 15;19(8):2153–2164
  47. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose escalation study in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2001 April 15;19(5):2165–2170
  48. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554–3561
  49. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology. 2006 May 20;24(15):2337–2342
  50. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 December 15;98(12):2657–2663
  51. Pavletic ZS, Bierman PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology. 1998 September;9(9):1023–1026
  52. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004 October 15;104(8):2600–2602
  53. Meloni G, Proia A, Mauro F, et al. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica. 2000 September;85(9):952–960
  54. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology. 2003 July 15;21(14):2747–2753
  55. Rai KR, Byrd JC, Peterson B, et al. A Phase2 Trial of Fludarabine followed by Alemtuzumab (Campath 1H) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients with Active Disease: cancer and Leukemia Group B (CALGB) Study 19901. Blood 100(11) 205a-Abstract number 772. 16-11-2002.
  56. Rai KR, Byrd J, Peterson B, et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia(CLL) :CAL GB study 19901. Blood 102(11) 676a-Abstract number 2506. 2003.

PII: S1521-6926(07)00041-2

doi: 10.1016/j.beha.2007.03.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 499-512 , September 2007

Article Tools

* Image Usage & Resolution